Vaccinex Shares Halted On Circuit Breaker To The Upside, Stock Now Up 51%
$VCNX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaccinex Shares Halted On Circuit Breaker To The Upside, Stock Now Up 51%
Save time and jump to the most important pieces.
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
8-K - VACCINEX, INC. (0001205922) (Filer)
10-Q - VACCINEX, INC. (0001205922) (Filer)
424B3 - VACCINEX, INC. (0001205922) (Filer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
4 - VACCINEX, INC. (0001205922) (Issuer)
Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update on its key program for Alzheimer's disease. Treatment with pepinemab believed to slow cognitive decline due to Alzheimer's disease: Vaccinex reported final data from its SIGNAL-AD clinical trial at the Alzheimer's Association In
ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing Vaccinex's ActivMAb® technology to generate antibodies to complex antigen targets. In addition, Vaccinex has signed agreements to provide Charles River Labs, OmniAb, Adimab and other undisclosed strategic partners with materials to facilitate their antibody discovery programs using transg
ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immunotherapy of Cancer's Annual Meeting (SITC) on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study (NCT04815720) for treatment of recurrent and metastatic disease
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session.
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)
SC 13G - VACCINEX, INC. (0001205922) (Subject)
SC 13D/A - VACCINEX, INC. (0001205922) (Subject)